Mitochondria may be affected in cardiovascular disease or pathological models.
Does your compound provide protection?
Cardiovascular diseases (CVD) remain the number one killer in developed countries, despite tremendous efforts to identify efficient therapies. Heart failure, atherosclerosis, myocardial infarction, cardiomyopathy, hypertension, etc. mitochondrial dysfunction contributes significantly to the pathogenesis of all these cardiovascular disorders.
Through our MitoXpert® platform, you have access to a wide range of assays investigating how compounds protect/restore cardiac mitochondrial function.
Our readouts allow you to extensively characterise your compound’s mode of action (MoA) on cardiac mitochondria. Our cellular assays using cardiac and vascular cells evaluate mitochondrial functionality from the following perspectives:
Assays can be performed in basal or pathological conditions, by provoking metabolic or oxidative stress, or implementing an ischaemia/reperfusion model (hypoxia and glucose deprivation).
Direct effect of compounds can also be assessed on isolated mitochondria from rodent hearts, in compliance with the 3R principle.